Catalyst Pharmaceuticals (CPRX) Assets Average (2011 - 2026)

Catalyst Pharmaceuticals has reported Assets Average for 16 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 27.91% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 27.91% YoY), and the FY2025 full-year result was $977.7 million, up 47.96% from the prior year.
• Assets Average for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Assets Average was $1.1 billion in Q1 2026, with the low at $242.4 million in Q1 2022.
• Historically, Assets Average has averaged $627.2 million across 5 years, with a median of $558.4 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average climbed 24.43% — and 2024, when it surged 83.79%.
• Catalyst Pharmaceuticals' Assets Average stood at $354.4 million in 2022, then gained by 24.63% to $441.7 million in 2023, then soared by 83.79% to $811.7 million in 2024, then surged by 32.78% to $1.1 billion in 2025, then advanced by 4.45% to $1.1 billion in 2026.
• The last three Assets Average figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.